GNCA
Income statement / Annual
Last year (2021), Genocea Biosciences, Inc.'s total revenue was $1.64 M,
an increase of 20.75% from the previous year.
In 2021, Genocea Biosciences, Inc.'s net income was -$15.42 M.
See Genocea Biosciences, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
FY-2013
|
FY-2012
|
| Period Ended |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
12/31/2013 |
12/31/2012 |
| Operating Revenue |
$1.64 M |
$1.36 M |
$0.00 |
$0.00 |
$0.00 |
$235,000.00 |
$670,000.00 |
$308,000.00 |
$731,000.00 |
$1.98 M |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$1.64 M
|
$1.36 M
|
$0.00
|
$0.00
|
$0.00
|
$235,000.00
|
$670,000.00
|
$308,000.00
|
$731,000.00
|
$1.98 M
|
| Gross Profit Ratio |
1
|
1
|
0
|
0
|
0
|
1
|
1
|
1
|
1
|
1
|
| Research and Development Expenses |
$39.02 M
|
$33.96 M
|
$26.95 M
|
$25.21 M
|
$39.20 M
|
$33.05 M
|
$28.05 M
|
$23.73 M
|
$15.70 M
|
$11.24 M
|
| General & Administrative Expenses |
$14.71 M
|
$14.39 M
|
$12.04 M
|
$14.31 M
|
$13.43 M
|
$15.43 M
|
$13.99 M
|
$9.75 M
|
$4.96 M
|
$3.69 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$14.71 M
|
$14.39 M
|
$12.04 M
|
$14.31 M
|
$13.43 M
|
$15.43 M
|
$13.99 M
|
$9.75 M
|
$4.96 M
|
$3.69 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$2.62 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$53.73 M
|
$48.35 M
|
$38.99 M
|
$39.52 M
|
$52.64 M
|
$48.48 M
|
$42.04 M
|
$33.47 M
|
$20.66 M
|
$14.93 M
|
| Cost And Expenses |
$53.73 M
|
$48.35 M
|
$38.99 M
|
$39.52 M
|
$52.64 M
|
$48.48 M
|
$42.04 M
|
$33.47 M
|
$20.66 M
|
$14.93 M
|
| Interest Income |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$250,000.00
|
$410,000.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
-$1.12 M
|
$1.38 M
|
$946,000.00
|
$1.02 M
|
$1.71 M
|
$1.74 M
|
$1.12 M
|
$970,000.00
|
$459,000.00
|
$507,000.00
|
| Depreciation & Amortization |
$17.78 M
|
$1.14 M
|
$1.10 M
|
$1.09 M
|
$1.52 M
|
$1.81 M
|
$1.05 M
|
$469,000.00
|
$318,000.00
|
$300,000.00
|
| EBITDA |
-$34.32 M |
-$41.20 M |
-$36.91 M |
-$25.70 M |
-$53.49 M |
-$46.02 M |
-$40.32 M |
-$33.86 M |
-$20.03 M |
-$12.56 M |
| EBITDA Ratio |
-20.91
|
-30.31
|
0
|
0
|
0
|
-195.84
|
-60.17
|
-109.93
|
-27.4
|
-6.35
|
| Operating Income Ratio |
-31.74
|
-34.58
|
0
|
0
|
0
|
-205.3
|
-61.74
|
-107.68
|
-27.26
|
-6.55
|
| Total Other Income/Expenses Net |
$18.90 M
|
$3.28 M
|
$39,000.00
|
$11.71 M
|
-$1.46 M
|
-$1.33 M
|
-$1.12 M
|
-$2.13 M
|
-$881,000.00
|
-$414,000.00
|
| Income Before Tax |
-$33.20 M
|
-$43.71 M
|
-$38.95 M
|
-$27.81 M
|
-$56.71 M
|
-$49.57 M
|
-$42.48 M
|
-$35.30 M
|
-$20.81 M
|
-$13.37 M
|
| Income Before Tax Ratio |
-20.23
|
-32.17
|
0
|
0
|
0
|
-210.95
|
-63.41
|
-114.6
|
-28.46
|
-6.76
|
| Income Tax Expense |
-$17.78 M
|
$4.66 M
|
$985,000.00
|
$12.73 M
|
$250,000.00
|
$410,000.00
|
$0.00
|
-$1.16 M
|
-$422,000.00
|
$93,000.00
|
| Net Income |
-$15.42 M
|
-$43.71 M
|
-$38.95 M
|
-$27.81 M
|
-$56.71 M
|
-$49.57 M
|
-$42.48 M
|
-$35.30 M
|
-$20.81 M
|
-$13.37 M
|
| Net Income Ratio |
-9.4
|
-32.17
|
0
|
0
|
0
|
-210.95
|
-63.41
|
-114.6
|
-28.46
|
-6.76
|
| EPS |
-0.22 |
-0.94 |
-1.89 |
-2.69 |
-15.86 |
-14.01 |
-13.89 |
-18.08 |
-9.67 |
-14.31 |
| EPS Diluted |
-0.22 |
-0.94 |
-1.89 |
-2.69 |
-15.86 |
-14.01 |
-13.89 |
-18.08 |
-9.67 |
-14.31 |
| Weighted Average Shares Out |
$68.58 M
|
$46.55 M
|
$20.64 M
|
$10.32 M
|
$3.58 M
|
$3.54 M
|
$3.06 M
|
$1.95 M
|
$2.15 M
|
$934,000.00
|
| Weighted Average Shares Out Diluted |
$68.58 M
|
$46.55 M
|
$20.64 M
|
$10.32 M
|
$3.58 M
|
$3.54 M
|
$3.06 M
|
$1.95 M
|
$2.15 M
|
$934,000.00
|
| Link |
|
|
|
|
|
|
|
|
|
|
